RxDoctor Payments Data

Abraham Rothman, MD

Pediatric Cardiology · Las Vegas, NVNPI 1730162074

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $127,938 of the $174,678 with a category attached, or 73.2%. Edwards Lifesciences accounts for 98.7% of it on its own, with 7 other manufacturers making up the rest.

$174,678in general payments, 2019–2025

Across 156 payments — averaging $1119.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$172K
  • Abbott$1K
  • Medtronic$648
  • Actelion Pharmaceuticals US, Inc.$276
  • Merck$143
  • E.r. Squibb & Sons, L.L.C.$117
  • plus $60 from 2 others
$101,519in research payments, 2019–2025

Across 57 payments — averaging $1781.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$74K
  • Edwards Lifesciences$27K

What the payments were for

  • Consulting fees$127,93873%
  • Speaking & faculty fees$13,7508%
  • Travel & lodging$29,40617%
  • Food & beverage$3,5842%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric cardiology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$10,026
Medicare patients
19
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag29$680,726
OpsumitMacitentan37$448,349
Orenitram ErTreprostinil Diolamine24$354,909
AdempasRiociguat12$163,674
Ambrisentan30$58,250
Tadalafil11$24,961
Sildenafil Citrate35$1,801
Furosemide13$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$276$1,129,07466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric cardiology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other pediatric cardiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →